Skip to main content

Peer Review reports

From: Prescribing trends of SGLT2 inhibitors among HFrEF and HFpEF patients with and without T2DM, 2013–2021

Original Submission
15 Feb 2024 Submitted Original manuscript
24 Mar 2024 Reviewed Reviewer Report
31 Mar 2024 Reviewed Reviewer Report - Erika Yamamoto
11 Apr 2024 Author responded Author comments - Jimmy Gonzalez
12 Apr 2024 Author responded Author comments - Jimmy Gonzalez
Resubmission - Version 2
11 Apr 2024 Submitted Manuscript version 2
15 Apr 2024 Author responded Author comments - Jimmy Gonzalez
Resubmission - Version 3
15 Apr 2024 Submitted Manuscript version 3
23 Apr 2024 Reviewed Reviewer Report
24 Apr 2024 Reviewed Reviewer Report - Erika Yamamoto
29 Apr 2024 Author responded Author comments - Jimmy Gonzalez
Resubmission - Version 4
29 Apr 2024 Submitted Manuscript version 4
18 May 2024 Author responded Author comments - Jimmy Gonzalez
Resubmission - Version 5
18 May 2024 Submitted Manuscript version 5
23 May 2024 Reviewed Reviewer Report
26 May 2024 Reviewed Reviewer Report - Erika Yamamoto
Resubmission - Version 6
Submitted Manuscript version 6
Publishing
26 May 2024 Editorially accepted
30 May 2024 Article published 10.1186/s12872-024-03961-5

You can find further information about peer review here.

Back to article page